News from Zyme and the companies we work with.

October 16, 19

Nonacus introduces ExomeCG product to simplify molecular and cytogenomics data generation and interpretation

New capture kit product will enable whole exome sequencing and targeted copy number analysis in a single assay  Birmingham, UK, 16 October 2019: Nonacus Ltd, a UK based precision medicine company and manufacturer of ultra-sensitive next-generation sequencing (NGS) products, has … Continue reading →

October 16, 19

Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells

GammaDelta Therapeutics spins-out new company to accelerate antibody-based assets towards clinical studies London, UK, 16th October 2019: GammaDelta Therapeutics, a company focussed on harnessing the unique properties of gamma delta (γδ) T-cells to develop transformational immunotherapies, today announced the formation … Continue reading →

October 15, 19

Enterprise Therapeutics awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel Modulator

Support for clinical development up to end of Phase 2 for ETD002, first-in-class TMEM16A potentiator for the treatment of all cystic fibrosis patients Milestone Funding through Cystic Fibrosis Foundation’s Therapeutics Development Award programme Brighton, UK, 15 October 2019: Enterprise Therapeutics … Continue reading →

October 14, 19

Femtogenix presents efficacy and toxicity data on antibody drug conjugates containing new generation of DNA-binding therapeutic payloads

Studies demonstrate superior efficacy and cytotoxicity of Femtogenix’s sequence-selective DNA-interactive payload molecules toward tumour cells Data presented at World ADC 2019, San Diego, CA Harpenden, UK, 14 October 2019: Femtogenix Ltd, a UK biotechnology company developing the next generation of … Continue reading →

October 14, 19

Mogrify raises additional $16 million to advance its mission to transform the development of life-saving cell therapies

Initial close of Series A funding brings the total raised to over $20 million to date Funding will accelerate Mogrify’s internal cell therapy programs, and the development and out-license of novel IP relating to cell conversions of broad therapeutic interest … Continue reading →

October 14, 19

CombiGene signs agreement with Cobra Biologics for production of candidate drug CG01

Collaboration supports progression of Epilepsy Gene Therapy toward clinical trials   Sweden, Lund and Keele, UK, 14th October 2019: CombiGene AB (publ) (“CombiGene”), a leading Nordic gene therapy company, today signed an agreement with the Anglo-Swedish Contract Development and Manufacturing … Continue reading →

October 10, 19

BIA Separations introduces Cornerstone Exosome Process Development Solution to enable industrial scale manufacture of therapeutic exosomes

Platform combines proprietary new technologies for high yield purification of exosomes: Kryptonase™ and CIMmultus™ EV monolithic column Coordinated purification process development service integrates BIA Separations’ expertise to accelerate progress to clinical trials, and scale-up manufacturing  Ajdovšcina, Slovenia, 10 October 2019: … Continue reading →

October 10, 19

Avacta Group plc enters collaboration and option agreement with ADC Therapeutics

Focus on developing potent Affimer-drug conjugates Cambridge, UK and Lausanne, Switzerland, 10 October 2019: Avacta Group plc (AIM: AVCT), a biotechnology company developing novel cancer immunotherapies based on its proprietary Affimer® platform, today announced that it has entered a collaboration … Continue reading →

October 10, 19

Optibrium introduces Augmented Chemistry™ services to guide successful drug discovery

CAMBRIDGE, UK, 10 October, 2019 – Optibrium™, a developer of software for drug discovery, today announced the introduction of its Augmented Chemistry™ services, which provide collaborators with novel artificial intelligence technologies to supplement their skills and experience, enabling them to … Continue reading →

October 8, 19

FUJIFILM Irvine Scientific Receives CE Mark Approval for Multiple ART Media

Innovative ART products now available in Europe SANTA ANA, California, 08 October, 2019: FUJIFILM Irvine Scientific, Inc., a world leader in the innovation, development and manufacture of cell culture media and Assisted Reproductive Technologies (ART), today announced the receipt of … Continue reading →